Inhibikase Therapeutics, Inc.
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
IKT | NDAQ
Overview
Corporate Details
- ISIN(s):
- US45719W2052
- LEI:
- Country:
- United States of America
- Address:
- 1000 N. WEST STREET, SUITE 1200, 19801 WILMINGTON
- Website:
- https://www.inhibikase.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development of small molecule protein kinase inhibitor therapeutics. The company's primary research is centered on creating treatments to modify the course of neurodegenerative conditions, particularly Parkinson's disease and related disorders. Its lead drug candidate, IkT-148009, is designed to halt disease progression by inhibiting the c-Abl protein kinase. In addition to its focus on neurodegeneration, the company is also developing therapies for other indications, such as pulmonary arterial hypertension.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Inhibikase Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Inhibikase Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Inhibikase Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
